These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28504552)

  • 1. Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid.
    Kruse N; El-Agnaf OM; Mollenhauer B
    Bioanalysis; 2017 Apr; 9(8):621-630. PubMed ID: 28504552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study.
    Kruse N; Persson S; Alcolea D; Bahl JM; Baldeiras I; Capello E; Chiasserini D; Bocchio Chiavetto L; Emersic A; Engelborghs S; Eren E; Fladby T; Frisoni G; García-Ayllón MS; Genc S; Gkatzima O; Heegaard NH; Janeiro AM; Kováčech B; Kuiperij HB; Leitão MJ; Lleó A; Martins M; Matos M; Mollergard HM; Nobili F; Öhrfelt A; Parnetti L; de Oliveira CR; Rot U; Sáez-Valero J; Struyfs H; Tanassi JT; Taylor P; Tsolaki M; Vanmechelen E; Verbeek MM; Zilka N; Blennow K; Zetterberg H; Mollenhauer B
    Neurobiol Aging; 2015 Sep; 36(9):2587-96. PubMed ID: 26093515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid.
    Kruse N; Schulz-Schaeffer WJ; Schlossmacher MG; Mollenhauer B
    Methods; 2012 Apr; 56(4):514-8. PubMed ID: 22465793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human α-Synuclein in cerebrospinal fluid.
    Kruse N; Mollenhauer B
    J Immunol Methods; 2015 Nov; 426():70-5. PubMed ID: 26271436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration.
    Miller AM; Rutkowska A; Bahl JM; Herukka SK; Koel-Simmelink MJ; Kruse N; Mollenhauer B; Siloaho M; Skinningsrud A; Zetterberg H; Teunissen CE; Lawlor BA
    Bioanalysis; 2016 Nov; 8(21):2243-2254. PubMed ID: 27684648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a new assay for α-synuclein detection in cerebrospinal fluid.
    Førland MG; Öhrfelt A; Oftedal LS; Tysnes OB; Larsen JP; Blennow K; Zetterberg H; Alves G; Lange J
    Clin Chem Lab Med; 2017 Feb; 55(2):254-260. PubMed ID: 27474841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of Alpha-Synuclein in Biological Fluids by Electrochemiluminescence-Based Detection.
    Kruse N; Mollenhauer B
    Methods Mol Biol; 2019; 1948():59-68. PubMed ID: 30771170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD.
    Llorens F; Kruse N; Schmitz M; Shafiq M; da Cunha JE; Gotzman N; Zafar S; Thune K; de Oliveira JR; Mollenhauer B; Zerr I
    J Neurol; 2015 Oct; 262(10):2305-11. PubMed ID: 26162713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.
    Simonsen AH; Kuiperij B; El-Agnaf OM; Engelborghs S; Herukka SK; Parnetti L; Rektorova I; Vanmechelen E; Kapaki E; Verbeek M; Mollenhauer B
    Biomark Med; 2016; 10(1):19-34. PubMed ID: 26314196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.
    Mollenhauer B; Bowman FD; Drake D; Duong J; Blennow K; El-Agnaf O; Shaw LM; Masucci J; Taylor P; Umek RM; Dunty JM; Smith CL; Stoops E; Vanderstichele H; Schmid AW; Moniatte M; Zhang J; Kruse N; Lashuel HA; Teunissen C; Schubert T; Dave KD; Hutten SJ; Zetterberg H
    J Neurochem; 2019 Apr; 149(1):126-138. PubMed ID: 30125936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study.
    Unterberger U; Lachmann I; Voigtländer T; Pirker W; Berghoff AS; Flach K; Wagner U; Geneste A; Perret-Liaudet A; Kovacs GG
    Clin Neuropathol; 2014; 33(5):329-34. PubMed ID: 25131945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases.
    Llorens F; Kruse N; Schmitz M; Gotzmann N; Golanska E; Thüne K; Zejneli O; Kanata E; Knipper T; Cramm M; Lange P; Zafar S; Sikorska B; Liberski PP; Mitrova E; Varges D; Schmidt C; Sklaviadis T; Mollenhauer B; Zerr I
    Alzheimers Dement; 2017 Jun; 13(6):710-719. PubMed ID: 27870938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.
    Antonelou RCh; Emmanouilidou E; Gasparinatos G; Velona T; Voumvourakis KI; Stefanis L
    J Neurochem; 2015 Aug; 134(4):748-55. PubMed ID: 25962981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson's disease diagnosis.
    Zhao H; Zhao J; Hou J; Wang S; Ding Y; Lu B; Wang J
    Protein Cell; 2017 Sep; 8(9):696-700. PubMed ID: 28555377
    [No Abstract]   [Full Text] [Related]  

  • 19. Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis.
    Parnetti L; Cicognola C; Eusebi P; Chiasserini D
    Biomark Med; 2016; 10(1):35-49. PubMed ID: 26643452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
    Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
    Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.